We offer virtual consultation to help patients whose physical limitations make travel to the clinic impossible
Yesterday the US Food and Drug Administration approved two new medications – both are shots & each is a combination of two different classes of medication in one shot: a basal long-acting insulin and a GLP-1 receptor agonist. The Novo Nordisk product combines Tresiba, an insulin not yet available in Canada and Victoza while the Sanofi product combines Lantus and Lyxumia, a GLP-1 agonist not yet available in Canada.
While it is likely that neither of these products will be available in Canada for a year or more it is good news for individuals with diabetes who are currently on two different shots – soon it may just be one shot, and at a lower price.
This photo shows Lantus & Victoza.
For more information see http://www.reuters.com/article/idUSKBN13G2K5.